Navigation Links
Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Date:6/20/2013

SAN DIEGO, June 20, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR) /bupropion SR) clinical data presentations taking place at the American Diabetes Association (ADA) 73rd Scientific Sessions, June 21-25, 2013.

ADA: McCormick Place Convention Center (West Building), Chicago, ILAbstract# 1056-P – "Combination Naltrexone/Bupropion Therapy Resulted in Clinically Meaningful Improvements in Weight and Quality of Life - Integrated Analysis of Four Phase 3 Trials"
Lead Author: Ronette L. Kolotkin

Abstract# 1130-P – "An Integrated Analysis of Weight Loss with Combination Naltrexone/Bupropion Therapy by BMI (Obesity) Classification"
Lead Author: Caroline M. Apovian

Abstract# 1149-P – "Early Improvement in Control of Eating Is Associated with Long-term Weight Loss - Integrated Analysis of Four Phase 3 Trials of Combination Naltrexone/Bupropion Treatment"
Lead Author: Ken Fujioka

All abstracts will be presented at General Poster Session 2, on Sunday, June 23, from 12:00 PM - 2:00 PM, in Hall F1 – Posters.

Abstract #1056-P will also be showcased in a Guided Audio Poster Tour at the Innovative Oral Agents–Innovative Discoveries session on Monday, June 24, from 1:00 PM - 2:00 PM.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
2. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
3. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
4. Orexigen Therapeutics to Host Full Year and Fourth Quarter 2012 Financial Results Conference Call and Webcast
5. Orexigen Therapeutics Announces Webcast of Upcoming Presentation at the Cowen & Co. Annual Health Care Conference
6. Orexigen Therapeutics to Present at Upcoming Investor Conferences
7. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
8. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
9. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
10. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
11. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... DIEGO , April 21, 2015   ... clinical-stage biopharmaceutical company leveraging its molecular adhesion and ... for sickle cell disease, heart failure, and arterial ... pivotal EPIC study of its lead ... has surpassed the halfway point. Consistent with prior ...
(Date:4/21/2015)... --  Tal Medical , a clinical-stage medical device ... other psychiatric disorders, today announced a $14 million ... a new institutional investor, and several prominent individual ... to drive the company,s clinical research programs in ... and scale up the organization. "Our ...
(Date:4/21/2015)... England , April 21, 2015 ... company with global reach, today announced the appointment of ... Dr Göran Ando as a Non-Executive Director.  Bryan Morton, ... will become Executive Chairman.   Lee ... he was Vice President, Head of Commercial for ...
Breaking Medicine Technology:Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 2Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 3Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 4Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Surpasses Halfway Mark 5Tal Medical Secures $14M Financing Round and Adds Industry Veterans to Team 2Tal Medical Secures $14M Financing Round and Adds Industry Veterans to Team 3EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 2EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 3
... Mass., Jan. 23, 2012  Virtify, Inc., will host an ... facilitate an open discussion by senior executives from four ... they are taking to comply with the July 2, ... follow. (Logo: http://photos.prnewswire.com/prnh/20110131/NE38689LOGO ) ...
...  As the influence of Managed Care continues to grow, ... out as part of interacting with the managed care ... an increased importance on these activities, as the strength ... success. On average, the Best Practices, LLC ...
Cached Medicine Technology:Roundtable of Industry Experts to Discuss Impact, Implications of EVMPD Mandate 2Pharmaceutical Industry Places Newfound Emphasis on Managed Care Organizations 2Pharmaceutical Industry Places Newfound Emphasis on Managed Care Organizations 3
(Date:4/21/2015)... York, NY (PRWEB) April 21, 2015 What ... Jessica Parker, Tom Ford and Ted Turner have in common? ... of the 50 Most Powerful Americans 50+. In a 16-page ... Chief of more than 50 magazines and 25 websites, along ... on the power they wield through the unique lens of ...
(Date:4/21/2015)... April 21, 2015 Carinsurancesavings.biz has released a ... under proper surveillance and explaining the impact on a ... vehicles safe and supervised may be eligible for advantageous auto ... in a simple and efficient way. This will also help ... convenient and simple way. , Finding low cost coverage is ...
(Date:4/21/2015)... eMindful, the provider of ... Gallagher as senior vice president of sales. Gallagher has ... leadership roles with major health insurance carriers, health care ... he managed national accounts for The Vitality Group, a ... consistently a top producer, sales manager and executive for ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 NOVAtime ... of enterprise Time and Attendance / Workforce Management ... Congress from the American Payroll Association (APA) as ... , The APA has been the nation’s payroll ... workshops, networking opportunities, and recertification credits. Held at ...
(Date:4/21/2015)... TN (PRWEB) April 21, 2015 ... clinical services and provider of Picture Archiving and ... area with four new installations in the first ... Springs, KY), Pinnacle Orthopaedics (McMinnville, TN) and Lowcountry ... the ProtonPACS viewer and data archiving services. Mt. ...
Breaking Medicine News(10 mins):Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 2Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 3Health News:NiC 50: 2015 Ranking of the Most Powerful Americans 50+ 4Health News:Auto Insurance Quotes Offer Excellent Security for A Car 2Health News:eMindful Continues to Expand Executive Leadership Team With Employee Benefits Sales Executive Michael Gallagher 2Health News:NOVAtime Participates in 2015 APA Congress and NetSuite SuiteWorld Conferences in May 2Health News:NOVAtime Participates in 2015 APA Congress and NetSuite SuiteWorld Conferences in May 3Health News:Radsource Adds 4 ProtonPACS Clients in 1st Quarter 2
... 3 HIV/AIDS drugs, Viraday that needs to be taken just ... three anti-HIV drugs efavirenz 600 mg, tenofovir 300 mg and ... alone effectively treats a HIV infected person, eliminates the need ... it is less burdensome and it can be taken along ...
... drug misoprostol, normally used to treat ulcers, was found ... death of women in developing countries, according// to a ... of Missouri, India's Jawaharlal Nehru Medical College, and the ... in the Oct. 8 issue of Lancet, found misoprostol ...
... at the Launceston General Hospital have developed a revolutionary ... of the LGH Dementia Research Centre George Razay merely ... type of dementia. ,Over 5000 Tasmanians are affected by ... by 2050. ,20 patients, equal number ...
... the intensive care unit previously occupied by ... the odds of acquiring such bacteria.// ... death in hospitals: methicillin-resistant Staphylococcus aureus (MRSA) ... information in the article. Researchers previously found ...
... Poor services are provided by doctors and dentists according ... trust which runs Barrowa€?s Furness General Hospital is rated ... has roundly criticised the NHS services in Cumbria. ... more wide-ranging and tougher than the old hotel-style star ...
... cell is a reservoir of proteins and performs the role of ... none other than the cell nucleus//, which houses the DNA, and ... particular protein is to be manufactured, the command is reproduced verbatim ... like substance, and is carried via pores in the cell nucleus ...
Cached Medicine News:Health News:Ulcer Drug Could Save Lives of Women in Developing Countries 2Health News:Transmission of Antibiotic-Resistant Bacteria Linked to Previous ICU Room Occupants 2Health News:The Living Cell – Manufacturing, Protecting and Thrivin 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: